Skip to main content
Top
Published in: Clinical Rheumatology 10/2011

01-10-2011 | Original Article

Gender and ethnicity differences in the prevalence of scleroderma-related autoantibodies

Authors: Malgorzata E. Krzyszczak, Yi Li, Steven J. Ross, Angela Ceribelli, Edward K. L. Chan, Michael R. Bubb, Eric S. Sobel, Westley H. Reeves, Minoru Satoh

Published in: Clinical Rheumatology | Issue 10/2011

Login to get access

Abstract

Autoantibodies to topoisomerase I (topo I), RNA polymerase III (RNAPIII), centromere, U3RNP/fibrillarin, Th, PM-Scl, and U1RNP found in scleroderma (SSc) are associated with unique clinical subsets. The effects of race and gender on autoantibody prevalence and clinical manifestations were examined. Autoantibodies in sera from 105 SSc (include 75 Caucasian, 24 African-American, 6 others; 89 females and 16 males) were analyzed by immunofluorescence and immunoprecipitation. Clinical information was from database. SSc-related autoantibodies seldom coexist except for anti-topo I and anti-U1RNP. Anti-topo I (35% vs 15%), anti-U3RNP (30% vs 3%, p = 0.0005), and anti-U1RNP (30% vs 13%) were more common in African-Americans vs Caucasians. Anti-centromere (17%) and anti-PM-Scl (only in 8% of female) were found only in Caucasians. In race/gender combination, all three African-American males had anti-topo I (p = 0.04). Anti-U3RNP (35% vs 3%, p = 0.0005) and anti-U1RNP were common in African-American females. In African-American, all nucleolar dominant staining sera had anti-U3RNP; nuclear pattern was topo I (50%), U1RNP (19%), and RNAPIII (13%). In Caucasian, nucleolar was anti-Th (43%) and PM-Scl (29%); nuclear pattern was RNAPIII (29%), topo I (24%), and U1RNP (18%). Anti-topo I, anti-RNAPIII, and anti-U3RNP were associated with diffuse SSc while anti-centromere, anti-Th, and anti-U1 with limited disease. Proximal scleroderma was less common in African-American with anti-topo I (38% vs 91% in Caucasian, p = 0.04). The production of SSc-related autoantibodies is gender and race dependent, and this can be highly relevant in understanding their clinical significance.
Literature
1.
go back to reference Satoh M, Chan EKL, Sobel ES, Kimpel DL, Yamasaki Y, Narain S, Mansoor R, Reeves WH (2007) Clinical implication of autoantibodies in patients with systemic rheumatic diseases. Expert Rev Clin Immunol 3:721–738PubMedCrossRef Satoh M, Chan EKL, Sobel ES, Kimpel DL, Yamasaki Y, Narain S, Mansoor R, Reeves WH (2007) Clinical implication of autoantibodies in patients with systemic rheumatic diseases. Expert Rev Clin Immunol 3:721–738PubMedCrossRef
2.
go back to reference Satoh M, Vazquez-Del Mercado M, Chan EK (2009) Clinical interpretation of antinuclear antibody tests in systemic rheumatic diseases. Mod Rheumatol 19:219–228PubMedCrossRef Satoh M, Vazquez-Del Mercado M, Chan EK (2009) Clinical interpretation of antinuclear antibody tests in systemic rheumatic diseases. Mod Rheumatol 19:219–228PubMedCrossRef
5.
go back to reference Ceribelli A, Cavazzana I, Franceschini F, Airo P, Tincani A, Cattaneo R, Pauley BA, Chan EK, Satoh M (2010) Anti-Th/To are common antinucleolar autoantibodies in Italian patients with scleroderma. J Rheumatol 37:2071–2075PubMedCrossRef Ceribelli A, Cavazzana I, Franceschini F, Airo P, Tincani A, Cattaneo R, Pauley BA, Chan EK, Satoh M (2010) Anti-Th/To are common antinucleolar autoantibodies in Italian patients with scleroderma. J Rheumatol 37:2071–2075PubMedCrossRef
6.
go back to reference Gussin HA, Ignat GP, Varga J, Teodorescu M (2001) Anti-topoisomerase I (anti-Scl-70) antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 44:376–383PubMedCrossRef Gussin HA, Ignat GP, Varga J, Teodorescu M (2001) Anti-topoisomerase I (anti-Scl-70) antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 44:376–383PubMedCrossRef
7.
go back to reference Hamidou MA, Audrain MA, Masseau A, Agard C, Moreau A (2006) Anti-topoisomerase I antibodies in systemic lupus erythematosus as a marker of severe nephritis. Clin Rheumatol 25:542–543PubMedCrossRef Hamidou MA, Audrain MA, Masseau A, Agard C, Moreau A (2006) Anti-topoisomerase I antibodies in systemic lupus erythematosus as a marker of severe nephritis. Clin Rheumatol 25:542–543PubMedCrossRef
8.
go back to reference Mahler M, Silverman ED, Schulte-Pelkum J, Fritzler MJ (2010) Anti-Scl-70 (topo-I) antibodies in SLE: myth or reality? Autoimmun Rev 9:755–760CrossRef Mahler M, Silverman ED, Schulte-Pelkum J, Fritzler MJ (2010) Anti-Scl-70 (topo-I) antibodies in SLE: myth or reality? Autoimmun Rev 9:755–760CrossRef
9.
go back to reference Cavazzana I, Angela C, Paolo A, Stefania Z, Angela T, Franco F (2009) Anti-RNA polymerase III antibodies: a marker of systemic sclerosis with rapid onset and skin thickening progression. Autoimmun Rev 8:580–584PubMedCrossRef Cavazzana I, Angela C, Paolo A, Stefania Z, Angela T, Franco F (2009) Anti-RNA polymerase III antibodies: a marker of systemic sclerosis with rapid onset and skin thickening progression. Autoimmun Rev 8:580–584PubMedCrossRef
10.
go back to reference Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23:581–590CrossRef Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23:581–590CrossRef
11.
go back to reference Satoh M, Ajmani AK, Ogasawara T, Langdon JJ, Hirakata M, Wang J, Reeves WH (1994) Autoantibodies to RNA polymerase II are common in systemic lupus erythematosus and overlap syndrome. Specific recognition of the phosphorylated (IIO) form by a subset of human sera. J Clin Invest 94:1981–1989PubMedCrossRef Satoh M, Ajmani AK, Ogasawara T, Langdon JJ, Hirakata M, Wang J, Reeves WH (1994) Autoantibodies to RNA polymerase II are common in systemic lupus erythematosus and overlap syndrome. Specific recognition of the phosphorylated (IIO) form by a subset of human sera. J Clin Invest 94:1981–1989PubMedCrossRef
12.
go back to reference Kuwana M, Kaburaki J, Arnett FC, Howard RF, Medsger TA Jr, Wright TM (1999) Influence of ethnic background on clinical and serologic features in patients with systemic sclerosis and anti-DNA topoisomerase I antibody. Arthritis Rheum 42:465–474PubMedCrossRef Kuwana M, Kaburaki J, Arnett FC, Howard RF, Medsger TA Jr, Wright TM (1999) Influence of ethnic background on clinical and serologic features in patients with systemic sclerosis and anti-DNA topoisomerase I antibody. Arthritis Rheum 42:465–474PubMedCrossRef
13.
go back to reference LeRoy EC, Medsger TA Jr (2001) Criteria for the classification of early systemic sclerosis. J Rheumatol 28:1573–1576PubMed LeRoy EC, Medsger TA Jr (2001) Criteria for the classification of early systemic sclerosis. J Rheumatol 28:1573–1576PubMed
14.
go back to reference Nadashkevich O, Davis P, Fritzler MJ (2004) A proposal of criteria for the classification of systemic sclerosis. Med Sci Monit 10:CR615–CR621PubMed Nadashkevich O, Davis P, Fritzler MJ (2004) A proposal of criteria for the classification of systemic sclerosis. Med Sci Monit 10:CR615–CR621PubMed
15.
go back to reference Welting TJ, Raijmakers R, Pruijn GJ (2003) Autoantigenicity of nucleolar complexes. Autoimmun Rev 2:313–321PubMedCrossRef Welting TJ, Raijmakers R, Pruijn GJ (2003) Autoantigenicity of nucleolar complexes. Autoimmun Rev 2:313–321PubMedCrossRef
16.
go back to reference Harris ML, Rosen A (2003) Autoimmunity in scleroderma: the origin, pathogenetic role, and clinical significance of autoantibodies. Curr Opin Rheumatol 15:778–784PubMedCrossRef Harris ML, Rosen A (2003) Autoimmunity in scleroderma: the origin, pathogenetic role, and clinical significance of autoantibodies. Curr Opin Rheumatol 15:778–784PubMedCrossRef
17.
go back to reference Walker UA, Tyndall A, Czirjak L, Denton CP, Farge-Bancel D, Kowal-Bielecka O, Muller-Ladner U, Matucci-Cerinic M (2009) Geographical variation of disease manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research (EUSTAR) group database. Ann Rheum Dis 68:856–862PubMedCrossRef Walker UA, Tyndall A, Czirjak L, Denton CP, Farge-Bancel D, Kowal-Bielecka O, Muller-Ladner U, Matucci-Cerinic M (2009) Geographical variation of disease manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research (EUSTAR) group database. Ann Rheum Dis 68:856–862PubMedCrossRef
18.
go back to reference Medsger TAJr (2001) Systemic sclerosis (scleroderma): clinical aspects. In: Koopman WJ (ed) Arthritis and allied conditions a textbook of rheumatology, vol 2, 14th edn. Lippincott Williams & Wilkins, Philadelphia, pp 1590–1624 Medsger TAJr (2001) Systemic sclerosis (scleroderma): clinical aspects. In: Koopman WJ (ed) Arthritis and allied conditions a textbook of rheumatology, vol 2, 14th edn. Lippincott Williams & Wilkins, Philadelphia, pp 1590–1624
19.
go back to reference Yamasaki Y, Honkanen-Scott M, Hernandez L, Ikeda K, Barker T, Bubb MR, Narain S, Richards HB, Chan EK, Reeves WH et al (2006) Nucleolar staining cannot be used as a screening test for the scleroderma marker anti-RNA polymerase I/III antibodies. Arthritis Rheum 54:3051–3056PubMedCrossRef Yamasaki Y, Honkanen-Scott M, Hernandez L, Ikeda K, Barker T, Bubb MR, Narain S, Richards HB, Chan EK, Reeves WH et al (2006) Nucleolar staining cannot be used as a screening test for the scleroderma marker anti-RNA polymerase I/III antibodies. Arthritis Rheum 54:3051–3056PubMedCrossRef
20.
go back to reference Wiik AS, Hoier-Madsen M, Forslid J, Charles P, Meyrowitsch J (2010) Antinuclear antibodies: a contemporary nomenclature using HEp-2 cells. J Autoimmun 35:276–290PubMedCrossRef Wiik AS, Hoier-Madsen M, Forslid J, Charles P, Meyrowitsch J (2010) Antinuclear antibodies: a contemporary nomenclature using HEp-2 cells. J Autoimmun 35:276–290PubMedCrossRef
21.
go back to reference Dellavance A, Gallindo C, Soares MG, da Silva NP, Mortara RA, Andrade LE (2009) Redefining the Scl-70 indirect immunofluorescence pattern: autoantibodies to DNA topoisomerase I yield a specific compound immunofluorescence pattern. Rheumatology (Oxford) 48:632–637CrossRef Dellavance A, Gallindo C, Soares MG, da Silva NP, Mortara RA, Andrade LE (2009) Redefining the Scl-70 indirect immunofluorescence pattern: autoantibodies to DNA topoisomerase I yield a specific compound immunofluorescence pattern. Rheumatology (Oxford) 48:632–637CrossRef
22.
go back to reference Okano Y, Medsger TA Jr (1990) Autoantibody to Th ribonucleoprotein (nucleolar 7–2 RNA protein particle) in patients with systemic sclerosis. Arthritis Rheum 33:1822–1828PubMedCrossRef Okano Y, Medsger TA Jr (1990) Autoantibody to Th ribonucleoprotein (nucleolar 7–2 RNA protein particle) in patients with systemic sclerosis. Arthritis Rheum 33:1822–1828PubMedCrossRef
23.
go back to reference Okano Y, Steen VD, Medsger TAJ (1992) Autoantibody to U3 nucleolar ribonucleoprotein(fibrillarin) in patients with systemic sclerosis. Arthritis Rheum 35:95–100PubMedCrossRef Okano Y, Steen VD, Medsger TAJ (1992) Autoantibody to U3 nucleolar ribonucleoprotein(fibrillarin) in patients with systemic sclerosis. Arthritis Rheum 35:95–100PubMedCrossRef
24.
go back to reference Steen VD, Ziegler GL, Rodnan GP, Medsger TA Jr (1984) Clinical and laboratory associations of anticentromere antibody in patients with progressive systemic sclerosis. Arthritis Rheum 27:125–131PubMedCrossRef Steen VD, Ziegler GL, Rodnan GP, Medsger TA Jr (1984) Clinical and laboratory associations of anticentromere antibody in patients with progressive systemic sclerosis. Arthritis Rheum 27:125–131PubMedCrossRef
25.
go back to reference LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, Rowell N, Wollheim F (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15:202–205PubMed LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, Rowell N, Wollheim F (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15:202–205PubMed
26.
go back to reference Steen VD, Medsger TA Jr (2000) Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 43:2437–2444PubMedCrossRef Steen VD, Medsger TA Jr (2000) Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 43:2437–2444PubMedCrossRef
27.
go back to reference Maddison PJ (2000) Mixed connective tissue disease: overlap syndromes. Baillières Best Pract Res Clin Rheumatol 14:111–124PubMedCrossRef Maddison PJ (2000) Mixed connective tissue disease: overlap syndromes. Baillières Best Pract Res Clin Rheumatol 14:111–124PubMedCrossRef
28.
go back to reference Jarzabek-Chorzelska M, Blaszczyk M, Jablonska S, Chorzelski T, Kumar V, Beutner EH (1986) Scl 70 antibody—a specific marker of systemic sclerosis. Br J Dermatol 115:393–401PubMedCrossRef Jarzabek-Chorzelska M, Blaszczyk M, Jablonska S, Chorzelski T, Kumar V, Beutner EH (1986) Scl 70 antibody—a specific marker of systemic sclerosis. Br J Dermatol 115:393–401PubMedCrossRef
29.
go back to reference Cruz M, Mejia G, Lavalle C, Cortes JJ, Reyes PA (1988) Antinuclear antibodies in scleroderma, mixed connective tissue disease and “primary” Raynaud’s phenomenon. Clin Rheumatol 7:80–86PubMedCrossRef Cruz M, Mejia G, Lavalle C, Cortes JJ, Reyes PA (1988) Antinuclear antibodies in scleroderma, mixed connective tissue disease and “primary” Raynaud’s phenomenon. Clin Rheumatol 7:80–86PubMedCrossRef
30.
go back to reference Meyer OC, Fertig N, Lucas M, Somogyi N, Medsger TA Jr (2007) Disease subsets, antinuclear antibody profile, and clinical features in 127 French and 247 US adult patients with systemic sclerosis. J Rheumatol 34:104–109PubMed Meyer OC, Fertig N, Lucas M, Somogyi N, Medsger TA Jr (2007) Disease subsets, antinuclear antibody profile, and clinical features in 127 French and 247 US adult patients with systemic sclerosis. J Rheumatol 34:104–109PubMed
31.
go back to reference Codullo V, Cavazzana I, Bonino C, Alpini C, Cavagna L, Cozzi F, Del Papa N, Franceschini F, Guiducci S, Morozzi G et al (2009) Serologic profile and mortality rates of scleroderma renal crisis in Italy. J Rheumatol 36:1464–1469PubMedCrossRef Codullo V, Cavazzana I, Bonino C, Alpini C, Cavagna L, Cozzi F, Del Papa N, Franceschini F, Guiducci S, Morozzi G et al (2009) Serologic profile and mortality rates of scleroderma renal crisis in Italy. J Rheumatol 36:1464–1469PubMedCrossRef
32.
go back to reference Faucher B, Stein P, Granel B, Weiller PJ, Disdier P, Serratrice J, Harle JR, Durand JM, Frances Y, Guis S et al (2010) Low prevalence of anti-RNA polymerase III antibodies in a French scleroderma population: anti-RNA polymerase III scleroderma. Eur J Intern Med 21:114–117PubMedCrossRef Faucher B, Stein P, Granel B, Weiller PJ, Disdier P, Serratrice J, Harle JR, Durand JM, Frances Y, Guis S et al (2010) Low prevalence of anti-RNA polymerase III antibodies in a French scleroderma population: anti-RNA polymerase III scleroderma. Eur J Intern Med 21:114–117PubMedCrossRef
Metadata
Title
Gender and ethnicity differences in the prevalence of scleroderma-related autoantibodies
Authors
Malgorzata E. Krzyszczak
Yi Li
Steven J. Ross
Angela Ceribelli
Edward K. L. Chan
Michael R. Bubb
Eric S. Sobel
Westley H. Reeves
Minoru Satoh
Publication date
01-10-2011
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 10/2011
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-011-1751-0

Other articles of this Issue 10/2011

Clinical Rheumatology 10/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.